Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
David Beckham reveals his Netflix documentary director was mad at him over viral 'be honest' momentSpain's Otaegui wins Volvo China OpenGeorgia governor signs budget boosting spending, looking to surplus billions to cut taxes in futureMy top diet tricks to lower your blood pressure WITHOUT taking pillsI was left with secondGeorgia governor signs budget boosting spending, looking to surplus billions to cut taxes in futureMet Gala 2024: Doja Cat boldly dons massive wet TPreakness status of Kentucky Derby winner Mystik Dan remains unclearShanghai rout Zhejiang as unbeaten run reaches 10Liverpool get back on track with 4
2.0101s , 6498.796875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Planet Panorama news portal